In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
about
Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptidesPromyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosisEpstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodiesRepression of PML nuclear body-associated transcription by oxidative stress-activated Bach2Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaThe transcriptional role of PML and the nuclear bodyPRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cellsLow-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell linesRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsAcute promyelocytic leukemia: from treatment to genetics and back.ASB-2 inhibits growth and promotes commitment in myeloid leukemia cells.Retinoic acid receptor alpha (RAralpha) Mutations in Human Leukemia.Transcription therapy for cancer.Genetic lesions and perturbation of chromatin architecture: a road to cell transformation.AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.In vivo analysis of the molecular genetics of acute promyelocytic leukemia.Transcriptional regulation in acute promyelocytic leukemia.Harnessing preclinical mouse models to inform human clinical cancer trials.Targeting expression of the leukemogenic PML-RARα fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosisEpigenetic regulation by RARα maintains ligand-independent transcriptional activity.Animal models of acute myelogenous leukaemia - development, application and future perspectives.Role of promyelocytic leukemia (PML) protein in tumor suppressionThe promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytesReview: genetic models of acute myeloid leukaemia.Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones.Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.A role for PML and the nuclear body in genomic stability.Some 1,2-diphenylethane derivatives as inhibitors of retinoic acid--metabolising enzymes.Some aryl substituted 2-(4-nitrophenyl)-4-oxo-4-phenylbutanoates and 3-(4-nitrophenyl)-1-phenyl-1,4-butanediols and related compounds as inhibitors of rat liver microsomal retinoic acid metabolising enzymes.Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells.
P2860
Q21090848-7AE239BA-B51C-450A-8D15-64B46160A74AQ22253228-9209ACE4-E0D6-4A1D-84B6-AA8D21EABBB5Q24529499-352327D8-C7F9-42E3-A2DC-130341CE4D22Q24602452-1BDDADFD-CF3F-4BAE-B920-396C7B229624Q24671020-C2294C46-89E4-46CC-98F2-61C661724B3AQ28144176-F8561460-5FA9-4409-9BA2-5D2C171D894BQ28212294-85DE4739-1CAE-4022-9A55-FBB003CCAE14Q28343498-16C58D0C-A70A-4ADA-911D-02483EA1E94EQ28344657-97707455-E1B3-4B3F-95AF-5C0A9289D4AEQ33739256-DC9C0BED-6903-494A-AF90-EEC5F58D9936Q34099506-8726A6F9-B0BC-4A0E-A7BC-88DDE0D6B215Q34244416-7190694C-BD7E-419E-A3CB-93A661989A1DQ34290301-64F20985-61FD-41A4-953C-BA8307E69952Q34349653-A4011695-ACDD-4392-83D8-C4DD9215D69EQ34405452-209CAF5C-D06F-4B61-A2A3-CBB1CB813FAAQ34405484-F51B314F-C7A5-48F7-BAD3-A72ECAD3FF49Q34435531-B8686800-9EED-4020-862C-4FE8A7C4725BQ34498952-2A8A4AE2-1B68-47BD-885E-A6832C0F495BQ35612561-D559058B-C68C-402F-97DC-922B818720BDQ35633556-39E3EAD4-85AF-4567-BA53-1CC7BD068B52Q36066980-16CAEFD8-D5A4-452D-B24F-9AEBD544C55DQ36376155-77E361BC-E0D1-4CDE-AE46-64CB8CA21AD3Q36603944-F3843CF1-4396-4FF3-A878-4E49E105CAB5Q37080843-E2E5AE20-7D84-4FE7-B0E2-F297D833A76CQ38487393-AC6CAFC9-1B3A-4802-BD06-9C80C5C5D565Q38833595-9EF4D62D-0906-464A-A761-B45C406F9F8AQ40905918-D95BDC06-FE21-4FBE-B10E-5DA854892B23Q44704024-C9E42EF8-4029-4803-ADCB-7FF7BB611391Q44791558-8828673E-BF4C-4209-BB3E-DDA7E8348D16Q45111080-5F59263C-0559-4C98-8F71-F8FA4FAF55AA
P2860
In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
In vivo analysis of the molecu ...... its therapeutic implications.
@ast
In vivo analysis of the molecu ...... its therapeutic implications.
@en
type
label
In vivo analysis of the molecu ...... its therapeutic implications.
@ast
In vivo analysis of the molecu ...... its therapeutic implications.
@en
prefLabel
In vivo analysis of the molecu ...... its therapeutic implications.
@ast
In vivo analysis of the molecu ...... its therapeutic implications.
@en
P2093
P2860
P356
P1433
P1476
In vivo analysis of the molecu ...... its therapeutic implications.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203088
P407
P577
1999-09-01T00:00:00Z
P5875
P6179
1033842070